Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/180102
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hanna, Catherine R. | - |
dc.contributor.author | Robles Zurita, José A. | - |
dc.contributor.author | Briggs, Andrew | - |
dc.contributor.author | Harkin, Andrea | - |
dc.contributor.author | Kelly, Caroline | - |
dc.contributor.author | McQueen, John | - |
dc.contributor.author | Allan, Karen | - |
dc.contributor.author | Pearson, Sarah | - |
dc.contributor.author | Hollander, Henrik | - |
dc.contributor.author | Glimelius, Bengt | - |
dc.contributor.author | Salazar Soler, Ramón | - |
dc.contributor.author | Segelov, Eva | - |
dc.contributor.author | Saunders, Mark | - |
dc.contributor.author | Iveson, Tim | - |
dc.contributor.author | Jones, Robert J. | - |
dc.contributor.author | Boyd, Kathleen A. | - |
dc.date.accessioned | 2021-09-17T11:54:47Z | - |
dc.date.available | 2021-09-17T11:54:47Z | - |
dc.date.issued | 2021-09-01 | - |
dc.identifier.issn | 1533-0028 | - |
dc.identifier.uri | http://hdl.handle.net/2445/180102 | - |
dc.description.abstract | Background: The Short Course Oncology Treatment (SCOT) trial demonstrated non-inferiority, less toxicity, and cost-effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Patients and methods: Individual cost-utility analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial (N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost-utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5-year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Results: Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. Conclusion: This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.clcc.2021.04.001 | - |
dc.relation.ispartof | Clinical Colorectal Cancer, 2021, vol. 20,num. 3, p. 236-244 | - |
dc.relation.uri | https://doi.org/10.1016/j.clcc.2021.04.001 | - |
dc.rights | cc by (c) Hanna, Catherine R. et al, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer colorectal | - |
dc.subject.classification | Economia de la salut | - |
dc.subject.other | Cancer chemotherapy | - |
dc.subject.other | Medical economics | - |
dc.title | Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-09-16T08:56:52Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33992542 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS1533002821000293.pdf | 962.87 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License